- Home
- RARE vs XMTR Comparison
RARE vs XMTR Comparison
Compare RARE & XMTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- XMTR
- Stock Information
- Founded
- RARE 2010
- XMTR 2013
- Country
- RARE United States
- XMTR United States
- Employees
- RARE N/A
- XMTR N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- XMTR Industrial Machinery/Components
- Sector
- RARE Health Care
- XMTR Technology
- Exchange
- RARE Nasdaq
- XMTR Nasdaq
- Market Cap
- RARE 2.6B
- XMTR 2.4B
- IPO Year
- RARE 2014
- XMTR 2021
- Fundamental
- Price
- RARE $29.96
- XMTR $49.48
- Analyst Decision
- RARE Strong Buy
- XMTR Buy
- Analyst Count
- RARE 14
- XMTR 11
- Target Price
- RARE $86.64
- XMTR $37.00
- AVG Volume (30 Days)
- RARE 1.4M
- XMTR 1.1M
- Earning Date
- RARE 08-05-2025
- XMTR 08-05-2025
- Dividend Yield
- RARE N/A
- XMTR N/A
- EPS Growth
- RARE N/A
- XMTR N/A
- EPS
- RARE N/A
- XMTR N/A
- Revenue
- RARE $610,159,000.00
- XMTR $603,762,000.00
- Revenue This Year
- RARE $19.72
- XMTR $22.43
- Revenue Next Year
- RARE $23.29
- XMTR $17.51
- P/E Ratio
- RARE N/A
- XMTR N/A
- Revenue Growth
- RARE 26.77
- XMTR 20.19
- 52 Week Low
- RARE $25.81
- XMTR $16.11
- 52 Week High
- RARE $60.37
- XMTR $51.26
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- XMTR 66.01
- Support Level
- RARE $29.04
- XMTR $47.29
- Resistance Level
- RARE $30.61
- XMTR $51.26
- Average True Range (ATR)
- RARE 0.80
- XMTR 2.41
- MACD
- RARE 0.31
- XMTR 0.02
- Stochastic Oscillator
- RARE 79.81
- XMTR 77.62
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.